Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Net Resources International

13:57 EDT 23rd June 2018 | BioPortfolio

Here are the most relevant search results for "Net Resources International" found in our extensive news archives from over 250 global news sources.

More Information about Net Resources International on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Net Resources International for you to read. Along with our medical data and news we also list Net Resources International Clinical Trials, which are updated daily. BioPortfolio also has a large database of Net Resources International Companies for you to search.

Showing News Articles 1–25 of 494 from Net Resources International

Thursday 21st June 2018

SillaJen enrols first patient in REN026 trial

South Korean biotechnology company SillaJen has enrolled the first patient in the REN026 trial in the US. REN026 is a...Read More... The post SillaJen enrols first patient in REN026 trial appeared first on Drug Development Technology.

Deals this week: Trevena, Compugen, Biohaven Pharmaceutical

Trevena plans to raise $175m through a public offering of securities. Trevena plans to issue common stock, debt securities, and...Read More... The post Deals this week: Trevena, Compugen, Biohaven Pharmaceutical appeared first on Drug Development Technology.

M&As this week: Orion Biotechnology Canada, SOPHiA GENETICS, GI Partners

Orion Biotechnology Canada has completed the acquisition of K2Biomedical for an undisclosed sum. K2Biomedical will operate as Orion Biotechnology Poland,...Read More... The post M&As this week: Orion Biotechnology Canada, SOPHiA GENETICS, GI Partners appeared first on Drug Development Technology.

CStone enrols first patient in Phase I trial of CS3006

CStone Pharmaceuticals has enrolled the first patient in a Phase l clinical trial of CS3006 for the treatment of patients...Read More... The post CStone enrols first patient in Phase I trial of CS3006 appeared first on Drug Development Technology.

Ironwood begins two Phase III trials of IW-3718

Ironwood Pharmaceuticals has commenced two Phase III clinical trials to examine the safety and efficacy of IW-3718 in patients with...Read More... The post Ironwood begins two Phase III trials of IW-3718 appeared first on Drug Development Technology.

Wednesday 20th June 2018

Anika reports negative top-line results from 16-02 trial of Cingal

Anika Therapeutics has reported negative top-line data in the 16-02 trial, a Phase III clinical study evaluating Cingal to treat...Read More... The post Anika reports negative top-line results from 16-02 trial of Cingal appeared first on Drug Development Technology.

Aminex receives approval to start Phase l trial of AMXT 1501

Aminex Therapeutics has received approval from the US Food and Drug Administration (FDA) to begin a Phase l clinical trial...Read More... The post Aminex receives approval to start Phase l trial of AMXT 1501 appeared first on Drug Development Technology.

Marinus starts Phase lll trial of ganaxolone for CDD

Marinus Pharmaceuticals has commenced a pivotal Phase lll clinical trial called Marigold Study to investigate the use of oral ganaxolone...Read More... The post Marinus starts Phase lll trial of ganaxolone for CDD appeared first on Drug Development Technology.

Another BACE inhibitor fails in phase III trials

On June 12, AstraZeneca and Eli Lilly terminated their two Phase III clinical trials of oral amyloid targeting β-secretase (BACE)...Read More... The post Another BACE inhibitor fails in phase III trials appeared first on Drug Development Technology.

Tuesday 19th June 2018

Arrowhead ends enrolment in AROAAT1001 trial

Arrowhead Pharmaceuticals has completed patient enrolment in the Phase l AROAAT1001 trial of ARO-AAT for Treatment of Alpha-1 Liver Disease....Read More... The post Arrowhead ends enrolment in AROAAT1001 trial appeared first on Drug Development Technology.

Sol-Gel doses first patient in Phase III trial of Epsolay

Sol-Gel Technologies has dosed the first patient in a pivotal Phase III clinical trial programme designed to analyse the safety...Read More... The post Sol-Gel doses first patient in Phase III trial of Epsolay appeared first on Drug Development Technology.

Agios starts Activate trial for pyruvate kinase deficiency

Agios Pharmaceuticals has started the Activate trial, a Phase lll study analysing the efficacy and safety of AG-348 for the...Read More... The post Agios starts Activate trial for pyruvate kinase deficiency appeared first on Drug Development Technology.

Monday 18th June 2018

Teva announces change in ENFORCE Phase III trial of fremanezumab

Teva Pharmaceutical Industries has announced a change in the ENFORCE Phase III clinical development programme of monoclonal antibody fremanezumab in...Read More... The post Teva announces change in ENFORCE Phase III trial of fremanezumab appeared first on Drug Development Technology.

MorphoSys presents data from Phase II trial of blood cancer drug

MorphoSys has presented clinical data from the Phase II COSMOS trial, which evaluated MOR208 in combination with the cancer drug...Read More... The post MorphoSys presents data from Phase II trial of blood cancer drug appeared first on Drug Development Technology.

Avedro starts enrolment in ACP-KXL-308 trial

Avedro has started patient enrolment in the ACP-KXL-308 trial, a pivotal Phase lll clinical study to examine the safety and...Read More... The post Avedro starts enrolment in ACP-KXL-308 trial appeared first on Drug Development Technology.

Sunday 17th June 2018

Apexigen and Yale Cancer Center test oncology combination therapy

US-based Apexigen has partnered with Yale Cancer Center to conduct a Phase I/II clinical trial of its APX005M candidate in...Read More... The post Apexigen and Yale Cancer Center test oncology combination therapy appeared first on Drug Development Technology.

Roche reports positive results from CLL11 study of obinutuzumab

Roche has reported positive results from the final analysis of the phase III study CLL11 assessing Gazyva/Gazyvaro (obinutuzumab)-based treatment in...Read More... The post Roche reports positive results from CLL11 study of obinutuzumab appeared first on Drug Development Technology.

NIH trial to assess vaccine against respiratory syncytial virus

US NIH division the National Institute of Allergy and Infectious Diseases (NIAID) has initiated a Phase I clinical trial to...Read More... The post NIH trial to assess vaccine against respiratory syncytial virus appeared first on Drug Development Technology.

Thursday 14th June 2018

Seattle Genetics doses first patient in innovaTV 204 trial

Seattle Genetics has dosed the first patient in the innovaTV 204 trial, a Phase ll study examining the efficacy, safety...Read More... The post Seattle Genetics doses first patient in innovaTV 204 trial appeared first on Drug Development Technology.

Prana receives approval for Phase l trial of PBT434

Prana Biotechnology has received approval from the ethics committee to begin a Phase I clinical trial to investigate the safety,...Read More... The post Prana receives approval for Phase l trial of PBT434 appeared first on Drug Development Technology.

Deals this week: InSphero, Ind-Swift Laboratories, Sage Therapeutics

InSphero has raised $10m in a funding round provided by internal and external investors. The funding round was led by Dr....Read More... The post Deals this week: InSphero, Ind-Swift Laboratories, Sage Therapeutics appeared first on Drug Development Technology.

ViiV reports positive Phase III outcomes for two-drug HIV regimen

GSK’s ViiV Healthcare has reported positive headline data from the Phase III GEMINI clinical programme of its two-drug regimen of...Read More... The post ViiV reports positive Phase III outcomes for two-drug HIV regimen appeared first on Drug Development Technology.

Wednesday 13th June 2018

CStone Pharmaceuticals starts two Phase II trials of CS1001

China-based CStone Pharmaceuticals has commenced two pivotal Phase II trials designed to evaluate the efficacy and safety of CS1001 to...Read More... The post CStone Pharmaceuticals starts two Phase II trials of CS1001 appeared first on Drug Development Technology.

AstraZeneca and Lilly to abort Phase III lanabecestat clinical trials

AstraZeneca and Eli Lilly and Company (Lilly) are set to discontinue their Phase III clinical trials of lanabecestat for the...Read More... The post AstraZeneca and Lilly to abort Phase III lanabecestat clinical trials appeared first on Drug Development Technology.

Asterias enrols and doses first subject in Phase l trial of AST-VAC2

Asterias Biotherapeutics has enrolled and dosed the first subject in a Phase l clinical trial of AST-VAC2 for the treatment...Read More... The post Asterias enrols and doses first subject in Phase l trial of AST-VAC2 appeared first on Drug Development Technology.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks